Kakihana Y, Nishida O, Taniguchi T, et al. - Whether landiolol, an ultra-short-acting β-blocker, affords a safe as well as efficacious treatment option for patients experiencing sepsis-related tachyarrhythmias, was investigated in this multicentre, open-label, randomised controlled trial at 54 hospitals in Japan. Enrollment of patients was performed who were admitted to the ICUs and managed with conventional treatment for sepsis, as per clinical guidelines for the management of sepsis, and who subsequently encountered a tachyarrhythmia. As per findings, landiolol use in patients with sepsis-related tachyarrhythmia afforded achievement of a heart rate of 60–94 beats per min at 24 h in significantly more patients and also conferred a significant decrease in the incidence of new-onset arrhythmia. Although good tolerability of landiolol was evident, but experts recommended using it under appropriate monitoring of blood pressure and heart rate on account of the risk of hypotension in patients with sepsis and septic shock.